Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439469 | 0.87 | LMNA (0.59) | LMNAMAPTCYP19A1NR3C1PGR | |
| SCHEMBL4455690 | 0.86 | LMNA (0.55) | LMNAMAPTCYP19A1NR3C1PGR | |
| SCHEMBL4807382 | 0.84 | LMNA (0.59) | LMNAMAPTCYP19A1NR3C1PGR | |
| SCHEMBL4444218 | 0.83 | AR (0.61) | LMNAMAPTNR3C1PGRCYP3A4 | |
| SCHEMBL5195019 | 0.82 | LMNA (0.59) | LMNAMAPTCYP19A1NR3C1PGR | |
| SCHEMBL3679824 | 0.78 | NR3C1 (0.64) | LMNANR3C1PGRCYP3A4ABCC3 | |
| SCHEMBL6447018 | 0.77 | LMNA (0.65) | LMNAMAPTCYP19A1NR3C1PGR | |
| SCHEMBL6449571 | 0.77 | LMNA (0.65) | LMNAMAPTCYP19A1NR3C1PGR | |
| SCHEMBL11817969 | 0.77 | LMNA (0.62) | LMNAMAPTCYP19A1PGRCYP3A4 | |
| SCHEMBL4210068 | 0.76 | LMNA (0.59) | LMNAMAPTCYP19A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2026818-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | Bodor, Nicholas S. (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2007142842-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2007-12-13 | — | — | WO | claimed |
| EP-2026818-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | Bodor, Nicholas S. (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007142842-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1653974-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR, Nicholas S. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050026892-A1 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | BODOR LABORATORIES, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005000317-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR NICHOLAS S (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026892-A1 | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application | OXER1, ELOVL6, ELOVL3 | LMNA 1749/4885MAPT 4856/4885CYP19A1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.